Digest Network Come funziona
Network
/
Società
Co
Non verificato

Coya Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

65 comunicati stampa

Guarda tutti i comunicati
10/11/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Sanità
Salute
Medicina - Varie
Coya Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
28/10/2026
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
Eventi
Industria
Coya Therapeutics to Present Neurofilament Light Chain (NfL) Biomarker Stratification Methodology in the ALSTARS Trial to Minimize the Impact of Heterogeneity in ALS Clinical Trials at the 2026 Annual NEALS Meeting
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
14/10/2026
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
13/10/2026
Salute
Igiene alimentare
Sanità
Medicina - Varie
Biotecnologia
Eventi
Coya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare Conference
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
05/10/2026
Industria
Scienza
Medicina - Varie
Sanità
Biotecnologia
Farmaceutica
Salute
Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
15/09/2026
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Analisi di mercato
Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
08/09/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
11/08/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Salute
Medicina - Varie
Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
18/06/2026
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
15/06/2026
Web e Social Network
Scienza
Sport
Medicina - Varie
Calcio
Biotecnologia
Salute
Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0